Healthcare provider profile · identity verified

David R Barile, MD

Internal Medicine · PRINCETON, NJ · NPI 1063461283

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	231	43
Atorvastatin Calcium	Atorvastatin Calcium	229	43
Amlodipine Besylate	Amlodipine Besylate	196	40
Mirtazapine	Mirtazapine	180	33
Metoprolol Succinate	Metoprolol Succinate	160	29
Trazodone Hcl	Trazodone Hcl	153	34
Furosemide	Furosemide	141	35
Losartan Potassium	Losartan Potassium	130	19
Eliquis	Apixaban	122	26
Rosuvastatin Calcium	Rosuvastatin Calcium	115	22
Sertraline Hcl	Sertraline Hcl	113	23
Buspirone Hcl	Buspirone Hcl	110	18
Omeprazole	Omeprazole	110	22
Quetiapine Fumarate	Quetiapine Fumarate	108	19
Prednisone	Prednisone	106	71
Escitalopram Oxalate	Escitalopram Oxalate	103	23
Meloxicam	Meloxicam	99	19
Gabapentin	Gabapentin	97	20
Carbidopa-Levodopa	Carbidopa/Levodopa	90	16
Lisinopril	Lisinopril	87	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	83	15
Memantine Hcl	Memantine Hcl	79	12
Tamsulosin Hcl	Tamsulosin Hcl	79	16
Clopidogrel	Clopidogrel Bisulfate	68	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	64	suppressed
Donepezil Hcl	Donepezil Hcl	64	suppressed
Divalproex Sodium	Divalproex Sodium	63	14
Famotidine	Famotidine	60	11
Metformin Hcl	Metformin Hcl	60	14
Duloxetine Hcl	Duloxetine Hcl	59	suppressed
Potassium Chloride	Potassium Chloride	58	13
Carvedilol	Carvedilol	53	suppressed
Latanoprost	Latanoprost	49	suppressed
Metformin Hcl Er	Metformin Hcl	47	suppressed
Tramadol Hcl	Tramadol Hcl	46	11
Alprazolam	Alprazolam	42	13
Bumetanide	Bumetanide	42	suppressed
Finasteride	Finasteride	41	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	40	suppressed
Digoxin	Digoxin	38	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	38	suppressed
Levofloxacin	Levofloxacin	38	27
Memantine Hcl Er	Memantine Hcl	36	suppressed
Ondansetron Hcl	Ondansetron Hcl	36	15
Fluticasone Propionate	Fluticasone Propionate	35	suppressed
Temazepam	Temazepam	35	suppressed
Lansoprazole	Lansoprazole	34	suppressed
Torsemide	Torsemide	34	suppressed
Pregabalin	Pregabalin	33	suppressed
Simvastatin	Simvastatin	32	suppressed
Primidone	Primidone	31	suppressed
Clonazepam	Clonazepam	30	suppressed
Januvia	Sitagliptin Phosphate	30	suppressed
Entresto	Sacubitril/Valsartan	28	suppressed
Ipratropium Bromide	Ipratropium Bromide	28	16
Valsartan	Valsartan	28	suppressed
Atenolol	Atenolol	27	suppressed
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	24	suppressed
Myrbetriq	Mirabegron	24	suppressed
Topiramate	Topiramate	24	suppressed
Spironolactone	Spironolactone	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Lorazepam	Lorazepam	22	15
Midodrine Hcl	Midodrine Hcl	22	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Risperidone	Risperidone	21	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	21	suppressed
Fluocinonide	Fluocinonide	20	14
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	18
Fluconazole	Fluconazole	19	15
Hydrocortisone	Hydrocortisone	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Metolazone	Metolazone	18	suppressed
Nystatin	Nystatin	18	14
Glipizide	Glipizide	17	suppressed
Azithromycin	Azithromycin	16	13
Raloxifene Hcl	Raloxifene Hcl	16	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Allopurinol	Allopurinol	14	suppressed
Carbamazepine Er	Carbamazepine	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Methenamine Hippurate	Methenamine Hippurate	14	suppressed
Morphine Sulfate	Morphine Sulfate	14	13
Ziprasidone Hcl	Ziprasidone Hcl	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	13	suppressed
Cephalexin	Cephalexin	13	12
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	13	suppressed
Nyamyc	Nystatin	13	11
Propranolol Hcl	Propranolol Hcl	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Anastrozole	Anastrozole	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Budesonide Dr	Budesonide	12	suppressed
Calcitriol	Calcitriol	12	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Linzess	Linaclotide	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Perphenazine	Perphenazine	11	suppressed
Rasagiline Mesylate	Rasagiline Mesylate	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Wellbutrin Sr	Bupropion Hcl	11	suppressed
Zenpep	Lipase/Protease/Amylase	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error